

NWT Clinical Practice Information Notice

Upon receipt, please file this notice in
Section C, Clinical Practice Information Binder for future reference.

The following clinical practice has been approved for use in the Northwest Territories Health and Social Services system, and has been distributed to:

<input checked="" type="checkbox"/>	Hospitals	<input checked="" type="checkbox"/>	Community Health Center	<input checked="" type="checkbox"/>	Homecare		LTCF	<input checked="" type="checkbox"/>	Lab Directors
<input checked="" type="checkbox"/>	Doctors' Offices		Social Services Offices	<input checked="" type="checkbox"/>	Public Health Units		Other		

The information contained in this document is a Departmental:									
	Policy		Standard	<input checked="" type="checkbox"/>	Protocol		Procedure		Guideline

Title: RSV Prophylaxis Protocol for Eligible Premature Infants
Effective Date: October 2008

Statement of approved Clinical Practice:

The NWT Advisory Committee on Immunization has revised the NWT *RSV Prophylaxis Protocol for Eligible Premature Infants*. Eligibility criteria for the 2008-09 season will now include:


1. All premature infants <32 weeks who are less than 6 months of age at the start of the RSV season.
2. Children 24 months or younger with bronchopulmonary dysplasia (BPD) or chronic lung disease due to prematurity who required oxygen within six months of the RSV season.
3. Infants with hemodynamically significant cardiac disease.
4. Infants 33 – 35 week gestation from *remote communities may be considered.
5. Down Syndrome infants less than 1 year old.

Please replace the December 2004 RSV Protocol in your manual.

Attachment: Revised Synagis Form (October 2008)

*Remote Communities are characterized by low population density and a lack of access to physician services.

This clinical practice is approved.



 (signature)

Assistant Deputy Minister Chief Medical Health Officer Director, Child & Family Services Director, Adoptions

Synagis® Standing Order Form

For the prevention of serious lower Respiratory Syncytial Virus (RSV) disease in high-risk pediatric patients.

Dosage And Administration:

The recommended dose of Synagis® is 15 mg/kg of body weight. Patients, including those who develop an RSV infection, should continue to receive monthly doses throughout the RSV season. The first dose should be administered prior to commencement of the RSV season.

Administration of Prophylaxis:

Once a decision for the administration of prophylaxis is made, palivizumab can be given by a community/public health nurse who has completed the NWT Immunization Certification Program. There is no need to delay or modify routine immunizations including live virus vaccines when palivizumab prophylaxis is used.

Please refer to your **November 2004** NWT RSV guidelines for complete information.

Indication for prophylaxis:				
Gestational Age 28 - 32 weeks <input type="checkbox"/> <28 weeks <input type="checkbox"/>	Bronchopulmonary Dysplasia 1 - 2 yrs. of age <input type="checkbox"/> < 1 yrs. of age <input type="checkbox"/>	*Gestational Age 33–35 weeks &/or**Cardiac Disease <input type="checkbox"/>	Down Syndrome <1yrs. of age at the start of RSV season <input type="checkbox"/>	
Last Name:		First Name:		
HCP:		DOB:		
Gestational Age:	Birth Wt.:	Parent:		
Address:			Phone:	
Other Medical Concerns:				
Family Physician/Nurse:			Referral Physician:	
	Weight	Dosage 15mg/kg	Administered by:	Date: Y/M/D
Rx for Synagis	Initial dose/amount			
	Second dose/amount			
	Third dose/amount			
	Fourth dose/amount			
	Fifth dose/amount			
Notes:				
Signed:				Date:

*Not routine for infants 33 – 35 week gestation but may be considered.

**Infants with hemodynamically significant cardiac disease (*on recommendation by pediatric cardiology*)



Original: Pt. chart.

Copy Fax to: Office of the Chief Medical Health Officer - Fax (867) 873-0442

October 2008